Health

Pancreatic cancer pill shows biggest breakthrough in decades

A daily pill combining daraxonrasib with chemotherapy made tumours undetectable in about 8% of advanced pancreatic cancer patients in early trials.

newsroom@fifthbell.com

November 20, 2026

WHO says cause of Russian lab worker's death remains unknown

A daily pill combining daraxonrasib with chemotherapy has shown the most significant breakthrough in pancreatic cancer treatment in decades, with tumours becoming undetectable in some patients with one of the deadliest cancers.

In a phase I/II trial of 61 patients with advanced pancreatic cancer that had spread to other parts of the body, tumours stopped growing in 90% of patients. About 61% saw their tumours shrink or disappear, and in roughly 8% of patients—one in 12—tumours became undetectable on CT scans. Researchers followed patients for a median of 18 months, with 76.6% still alive a year after starting treatment.

Daraxonrasib is a targeted inhibitor that blocks mutations called KRAS, found in more than 90% of pancreatic tumours. The protein, nicknamed the "Death Star" because it resists drug treatment, sends signals telling cancer cells to keep growing. Daraxonrasib binds to the protein and blocks those signals.

Dr Wungki Park of Memorial Sloan Kettering Cancer Center, who presented the findings, said he had never seen so many tumours disappear in patients whose cancer had spread. "This is the closest to cure," he said. "We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival."

Cancer Research UK called the results "the biggest leap forward in decades" for pancreatic cancer patients. Dr Sam Godfrey of the charity told BBC News that the drug "has found a way of drugging the undruggable." Dr Rachna Shroff, a gastrointestinal cancer specialist at the University of Arizona, said she "started crying in the clinic" when she read earlier trial results showing the pill doubled average life expectancy.

Pancreatic cancer has the lowest survival rate of all common cancers in the UK. Half of all people diagnosed die within three months, and among those whose cancer has spread to other organs, only about 3% survive five years. In Britain, there are 11,500 diagnoses each year and around 10,200 deaths. In the United States, pancreatic cancer accounts for about 3% of all cancers and about 8% of cancer deaths, killing around 53,000 people annually.

Doctors stressed that longer studies are needed to understand whether any cancers can be put into remission and for how long. It remains unclear how long the treatment might keep the disease at bay, and it should not be seen as a cure. A phase-three international trial is now recruiting patients. Dr Madina Kara, head of research at Pancreatic Cancer UK, urged ministers to increase investment so more patients could participate in trials and ensure proven drugs reach patients quickly across the UK.